Cellectis shares plunge 14%, down 59% over three months after its accounts
The Paris-based biotech falls sharply at midday, after a rebound that had stalled under its resistance level. The session coincides with the publication of its nine-month accounts, which confirm its refocusing on in vivo genome editing.
A 14% drop that brings the stock back below its resistance level
The Cellectis share price loses 13.98% to €1.10, compared with €1.28 the previous day, while the CAC 40 is virtually flat. The decline erases the gain made at the start of the week: the stock had soared 15% on November 11 before falling the next day, and it remains up 3.82% over seven days.
Over three months, the stock has lost 59.1%. The price holds above the MM20 at €1.04 (a gap of +5.87%), but remains below the MM50 at €1.31 (-15.95%) and the MM200 at €2.56 (-56.99%). The €0.94 support level is 14.8% below the current price.
A net loss of $101.1 million over nine months and cash runway into 2028
The accounts published this Friday show a net loss of $101.1 million over nine months, compared with $41.3 million a year earlier. Revenues declined, with a $47.5 million drop linked to lower activity in the collaboration with AstraZeneca, and the strategic transformation is weighing on expenses.
Cash, including term deposits, reached $149 million, down $62 million since the end of 2025.
Management estimates that this amount covers requirements until the second half of 2028. Among the points cited in the publication: the discontinuation of the lasme-cel and eti-cel programs, and a workforce reduction of up to 70% over 2026-2027. On the pipeline side, preliminary clinical data are expected in the second half of 2027 for HEAL-101, currently in phase 1 in China.
